Getting specific: targeting Fc receptors in myasthenia gravis

Nature Reviews Neurology, Published online: 23 August 2021; doi:10.1038/s41582-021-00547-zA randomized, placebo-controlled trial has found the neonatal Fc receptor modulator efgartigimod to be an effective therapy for generalized myasthenia gravis. If a pending FDA application is approved, the treatment will be the first recombinant antibody-based therapy for selective IgG depletion, adding to a growing spectrum of treatment options for myasthenia gravis.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research